+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06504381

Study of DB107-RRV and DB107-FC with Radiation Therapy, With or Without Temozolomide, in Newly Diagnosed High Grade Glioma Patients

Led by University of California, San Francisco · Updated on 2026-03-11

70

Participants Needed

5

Research Sites

730 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of DB107-RRV and DB107-FC along with standard treatments in patients newly diagnosed with High Grade Glioma HGG, a type of brain tumor. This open-label, multicenter study aims to see if adding these investigational therapies after surgery and during radiation or chemotherapy offers clinical benefits compared to historical data. The study involves patients receiving maximum surgical tumor removal followed by radiation and temozolomide or radiation alone depending on their MGMT methylation status. Participants receive DB107-RRV directly into the brain during surgery and intravenously shortly afterward. Those without MGMT methylation get DB107-FC orally during radiation therapy, while those with low to high MGMT methylation receive DB107-FC alongside temozolomide and radiation. After radiation, additional doses of DB107-RRV are given intravenously, followed by cycles of DB107-FC with or without temozolomide based on patient group. Treatment continues until disease progression or study end, with some participants able to receive extended DB107-FC cycles. The study includes two phases Phase I focuses on safety and dosing, and Phase IIa evaluates effectiveness and long-term outcomes. Participants will undergo tumor resection and receive radiation and drug treatments according to group assignment. Researchers will monitor safety, adverse events, and tumor response using imaging and biomarker tests, including MGMT methylation and IDH1 mutation status. Blood samples will be collected for genomic marker analysis. The study tracks progression-free survival and overall survival up to 15 years. Regular assessments include clinical exams, laboratory tests, and imaging to evaluate treatment effects and patient health throughout the study.

CONDITIONS

Brief Title

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Research Team

S

Stephanie Lewis, RN

N

Neuro-Oncology New Patient Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here